公开(公告)号：US20180333461A1

公开(公告)日：2018-11-22

申请号：US15534023

申请日：2014-12-08

Applicant: THE UNIVERSITY OF QUEENSLAND

Inventor： Paul Robert YOUNG

IPC: A61K38/20 ,  A61K39/12

CPC classification number: A61K38/20 ,  A61K31/7016 ,  A61K31/7024 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/713 ,  A61K38/21 ,  A61K39/12 ,  A61K45/06 ,  C07K16/1081 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395 ,  A61K2300/00

Abstract: Disclosed are methods and compositions for the treatment or prevention of Flavivirus infections. In particular, the present invention discloses TLR4 antagonists for use in treating or preventing disease associated with Flavivirus infections, including Dengue virus infections.

公开(公告)号：US20180243543A1

公开(公告)日：2018-08-30

申请号：US15864043

申请日：2018-01-08

Applicant: QuadMedicine

Inventor： Seung Ki BAEK ,  Myun Hwan AHN

IPC: A61M37/00

CPC classification number: A61M37/0015 ,  A61K9/0021 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2037/0053 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/401 ,  Y02A50/465 ,  Y02A50/469

Abstract: Disclosed is a microneedle including at least one tip portion that is capable of penetrating the skin and includes a liquid medicine melted in the skin; a base portion supporting the at least one tip portion; and at least one guide portion that is provided between the at least one tip portion and the base portion, is made of a non-soluble material, and is protruded in a direction in which the at least one tip portion penetrates the skin to couple with the at least one tip portion. In accordance with such a configuration, the at least one tip portion may be instantly separated in a short time, whereby superior liquid medicine supplyability is exhibited.

公开(公告)号：US09867803B2

公开(公告)日：2018-01-16

申请号：US15600473

申请日：2017-05-19

Applicant: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD.

Inventor： Qingping Zeng ,  Andras Toro ,  John Bruce Patterson ,  Warren Stanfield Wade ,  Zoltan Zubovics ,  Yun Yang ,  Zhipeng Wu

IPC: A61K31/352 ,  C07D311/16 ,  C07D405/10 ,  C07D417/04 ,  A61K31/366 ,  C07D409/04 ,  C07D405/04 ,  C07D401/04 ,  C07D311/94 ,  C07D311/20 ,  C07D401/12 ,  C07D311/22 ,  C07D311/12 ,  C07D217/08 ,  C07D217/02 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/453 ,  A61K31/452 ,  A61K31/4439 ,  A61K31/4433 ,  A61K31/427 ,  A61K31/423 ,  A61K31/4184 ,  A61K31/4172 ,  A61K31/4155 ,  A61K31/415 ,  A61K31/4045 ,  A61K31/404 ,  A61K31/4025 ,  A61K31/381 ,  A61K31/37 ,  A61K31/343

CPC classification number: A61K31/366 ,  A61K31/343 ,  A61K31/352 ,  A61K31/37 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4172 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/427 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/452 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D217/02 ,  C07D217/08 ,  C07D311/12 ,  C07D311/16 ,  C07D311/20 ,  C07D311/22 ,  C07D311/94 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D417/04 ,  Y02A50/389 ,  Y02A50/393

Abstract: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

公开(公告)号：US20170368050A1

公开(公告)日：2017-12-28

申请号：US15648119

申请日：2017-07-12

Applicant: Duke University

Inventor： Soman N. Abraham ,  Ashley L. St. John

IPC: A61K31/47 ,  A61K31/4709 ,  A61K31/352 ,  A61K38/55 ,  G01N33/573 ,  G01N33/68 ,  A61K31/4535 ,  A61K31/55

CPC classification number: A61K31/47 ,  A61K31/352 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/55 ,  A61K38/55 ,  G01N33/573 ,  G01N33/6893 ,  G01N2333/175 ,  G01N2333/185 ,  G01N2333/475 ,  G01N2333/5412 ,  G01N2333/96433 ,  G01N2800/26 ,  G01N2800/50 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/397

Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.

公开(公告)号：US20170190734A1

公开(公告)日：2017-07-06

申请号：US15423469

申请日：2017-02-02

Applicant: Selcia Limited ,  Gilead Sciences, Inc.

Inventor： Caroline Aciro ,  Jean Yves Chiva ,  David Kenneth Dean ,  Adrian John Highton ,  Petr Jansa ,  Andrew John Keats ,  Linos Lazarides ,  Richard Mackman ,  Karine G. Poullennec ,  Adam James Schrier ,  Dustin Scott Siegel ,  Victoria Alexandra Steadman ,  Greg Watt

IPC: C07K5/02 ,  A61K38/12 ,  A61K45/06

CPC classification number: C07K5/0202 ,  A61K38/00 ,  A61K38/12 ,  A61K38/15 ,  A61K39/05 ,  A61K39/29 ,  A61K45/06 ,  C07D487/08 ,  C07D498/08 ,  C07D498/18 ,  C07D498/22 ,  C07K5/02 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/391 ,  Y02A50/393 ,  Y02A50/395

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

公开(公告)号：US20170165254A1

公开(公告)日：2017-06-15

申请号：US15116113

申请日：2015-02-05

Applicant: Kuppuswamy Nagarajan ,  GEORGETOWN UNIVERSITY

Inventor： Kuppuswamy Nagarajan ,  Radhakrishnan Padmanabhan ,  Siwaporn Boonyasuppayakorn

IPC: A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/357 ,  A61K45/06

CPC classification number: A61K31/47 ,  A61K31/357 ,  A61K31/4709 ,  A61K31/473 ,  A61K45/06 ,  C07D215/40 ,  C07D453/04 ,  Y02A50/385 ,  Y02A50/389 ,  Y02A50/393

Abstract: Methods of treating, preventing, and/or ameliorating a Flavivirus infection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor. These methods are useful in treating, preventing, and/or ameliorating Flavivirus infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus.

公开(公告)号：US09623022B2

公开(公告)日：2017-04-18

申请号：US15137997

申请日：2016-04-25

Applicant: Janssen Sciences Ireland UC ,  Medivir AB

Inventor： Kenneth Alan Simmen ,  Herman Augustinus De Kock ,  Pierre Jean-Marie Bernard Raboisson ,  Lili Hu ,  Abdellah Tahri ,  Dominique Louis Nestor Ghislain Surleraux ,  Karl Magnus Nilsson ,  Bengt Bertil Samuelsson ,  Åsa Annica Kristina Rosenquist ,  Vladimir Ivanov ,  Mikael Pelcman ,  Anna Karin Belfrage ,  Per-Ola Mikael Johansson ,  Sandrine Marie Helene Vendeville

IPC: A61K31/14 ,  A61K31/33 ,  A61K31/4709 ,  C07D245/04 ,  C07D277/56 ,  C07D417/04 ,  C07D487/04 ,  A61K31/427 ,  A61K38/21 ,  C07D401/14 ,  C07D417/14 ,  A61K45/06 ,  A61K38/05 ,  C07K5/078 ,  A61K31/7056

CPC classification number: C07D487/04 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07D245/04 ,  C07D277/56 ,  C07D401/14 ,  C07D417/04 ,  C07D417/14 ,  C07K5/06139 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393

Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

公开(公告)号：US20170086463A1

公开(公告)日：2017-03-30

申请号：US15375737

申请日：2016-12-12

Applicant: NBC MESHTEC, INC.

Inventor： Yoshie FUJIMORI ,  Tsuruo NAKAYAMA ,  Tetsuya SATO

IPC: A01N59/20 ,  C12N7/00 ,  A01N25/34 ,  A01N37/02 ,  A01N47/48

CPC classification number: A01N59/20 ,  A01N25/34 ,  A01N37/02 ,  A01N47/48 ,  A61K9/10 ,  A61K9/5184 ,  A61K33/18 ,  A61K33/24 ,  A61K33/34 ,  C12N7/00 ,  C12N2760/16063 ,  C12N2770/16063 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467

Abstract: An antiviral agent is provided which can inactivate a wide range of viruses. Products that include such an antiviral agent are also provided.The present invention provides an antiviral agent that contains as an active ingredient a particle of at least one kind of iodide composed of iodine and an element shown in Period 4 to Period 6 and Group 8 to Group 15 of a periodic table or at least one kind of monovalent copper compound. The antiviral agent of the present invention can be designed at a higher degree of freedom in terms of its constituents as compared to conventional antiviral agents. In addition, the antiviral agent can readily exhibit and maintain its antiviral activity because it doesn't require any pretreatments or special washing processes.

公开(公告)号：US09301949B2

公开(公告)日：2016-04-05

申请号：US13203351

申请日：2010-02-24

Applicant: Chelsea M. Byrd ,  Dongcheng Dai ,  Robert Jordan ,  Dennis E. Hruby

Inventor： Chelsea M. Byrd ,  Dongcheng Dai ,  Robert Jordan ,  Dennis E. Hruby

IPC: C07D495/04 ,  C07D495/14 ,  A61K31/44 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06 ,  C07D495/22

CPC classification number: C07D495/22 ,  A61K31/4365 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06 ,  C07D495/04 ,  C07D495/14 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395 ,  A61K2300/00

Abstract: Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

Abstract translation: 公开了通过以治疗有效量施用某些噻吩并吡啶衍生物化合物来治疗病毒感染的方法和药物组合物。 还公开了使用该化合物及其药物组合物的方法。 特别地，公开了由黄病毒引起的病毒感染的治疗和预防，即包括但不限于登革病毒，西尼罗河病毒，黄热病病毒，日本脑炎病毒和蜱传脑炎病毒。

公开(公告)号：US20160017009A1

公开(公告)日：2016-01-21

申请号：US14803020

申请日：2015-07-17

Applicant: PEPTINNOVATE LIMITED

Inventor： Anthony Robert Milnes Coates ,  Yanira Riffo-Vasquez ,  Peter Tormay

IPC: C07K14/35

CPC classification number: C07K14/35 ,  A61K38/00 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/395 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/471 ,  Y02A50/483

Abstract: The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof.

Abstract translation: 本发明涉及用于药物，特别是用于预防或治疗非癌症状况或缓解患者疼痛的肽分子或核酸分子。 本发明还涉及包含本发明的肽或核酸分子的药物组合物及其治疗方法。